OncoMatch/Clinical Trials/NCT05798897
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
Is NCT05798897 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies MT-601 for non-hodgkin lymphoma, adult.
Treatment: MT-601 — This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Performance status
KARNOFSKY/ECOG 0–1
Karnofsky score of ≥70 or performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
Demographics
Prior therapy
Cannot have received: allogeneic hematopoietic cell transplant
Receipt of allogeneic hematopoietic cell transplant (HCT) within 12 months; on immunosuppression or with evidence of donor/mixed chimera
Cannot have received: autologous hematopoietic cell transplant
Receipt of autologous HCT within 3 months
Cannot have received: CD19-directed CAR T cell therapy
Treatment with CD19-directed CAR T cell therapy within 3 months
Cannot have received: bispecific antibody
Treatment with bispecific antibody within 1 month
Cannot have received: antibody-drug conjugate
Treatment with antibody drug conjugates (ADC's) or PD-1/PD-L1 within 21 days
Cannot have received: anti-PD-1 therapy
Treatment with antibody drug conjugates (ADC's) or PD-1/PD-L1 within 21 days
Cannot have received: anti-PD-L1 therapy
Treatment with antibody drug conjugates (ADC's) or PD-1/PD-L1 within 21 days
Cannot have received: monoclonal antibodies impacting T cell function
Treatment with monoclonal antibodies impacting T cell function within 14 days
Cannot have received: systemic immunosuppression (systemic corticosteroids)
Exception: unless ≤5 mg/day oral prednisone or steroid equivalent
Treatment with systemic immunosuppression including systemic corticosteroids (unless ≤5 mg/day oral prednisone or steroid equivalent) within 14 days
Cannot have received: chemotherapy
Treatment with chemotherapy within 7 days
Cannot have received: live, attenuated vaccine
Treatment with a live, attenuated vaccine within 4 weeks
Cannot have received: antibody-drug conjugate
Treatment with antibody drug conjugates (ADC's) or PD-1/PD-L1 within 21 days
Cannot have received: anti-PD-1 therapy
Treatment with antibody drug conjugates (ADC's) or PD-1/PD-L1 within 21 days
Cannot have received: anti-PD-L1 therapy
Treatment with antibody drug conjugates (ADC's) or PD-1/PD-L1 within 21 days
Cannot have received: chemotherapy
Treatment with chemotherapy or biologics/monoclonal antibodies within 14 days
Cannot have received: biologics/monoclonal antibodies
Treatment with chemotherapy or biologics/monoclonal antibodies within 14 days
Cannot have received: radiation therapy
Treatment with radiation therapy within 7 days
Cannot have received: tyrosine kinase inhibitor
Treatment with a tyrosine kinase inhibitor (TKI) within 7 days or 5 half-lives (whichever is longer) before conditioning regimen
Cannot have received: hematopoietic growth factors
Hematopoietic growth factors <2 days
Cannot have received: experimental CAR T cell product
Exception: unless approved by Medical Monitor
Treatment with experimental CAR T cell product unless approved by Medical Monitor
Cannot have received: other cancer therapy including investigational agents
Treatment with other cancer therapy including investigational agents that do not fit in the above categories within 14 days
Cannot have received: major surgery
Major surgery within 14 days
Lab requirements
Blood counts
Hemoglobin ≥ 7.0 g/dL (can be transfused), ALC ≥ 300/μL (prior to apheresis only), ANC ≥ 750/μL and platelet count ≥ 50,000/μL (prior to the conditioning regimen only)
Kidney function
Serum creatinine ≤ 1.5X ULN or measured or calculated creatinine clearance ≥ 50 mL/min (prior to the conditioning regimen)
Liver function
Bilirubin ≤ 1.5X ULN (exception of bilirubin elevation due to Gilbert's syndrome 3X); AST and ALT ≤ 3X ULN
Cardiac function
left ventricular ejection fraction ≥ 45% (prior to the leukapheresis)
Adequate blood, liver, renal and cardiac function: Hemoglobin ≥ 7.0 g/dL (can be transfused), ALC ≥ 300/μL (prior to apheresis only), ANC ≥ 750/μL and platelet count ≥ 50,000/μL (prior to the conditioning regimen only); Bilirubin ≤ 1.5X ULN (exception of bilirubin elevation due to Gilbert's syndrome 3X); AST and ALT ≤ 3X ULN; Serum creatinine ≤ 1.5X ULN or measured or calculated creatinine clearance ≥ 50 mL/min (prior to the conditioning regimen); left ventricular ejection fraction ≥ 45% (prior to the leukapheresis)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- University of Colorado · Aurora, Colorado
- Colorado Blood Cancer Institute (Sarah Cannon) · Denver, Colorado
- University of Kansas Medical Center · Kansas City, Kansas
- Cornell · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05798897 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic hematopoietic cell transplant, autologous hematopoietic cell transplant, CD19-directed CAR T cell therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 100 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages